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Overexpression of α1-acid glycoprotein in transgenic
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Background: α1-Acid glycoprotein (α1-AGP) is an acute phase protein in most mammalian species
whose concentration rises 2–5-fold during an acute phase reaction. Its serum concentration has often
been used as a marker of disease, including inflammatory bowel disease (IBD). High α1-AGP levels
were found to have a prognostic value for an increased risk of relapse in IBD.
Aims: To investigate a possible role for increased serum levels of α1-AGP in the development of IBD.
Methods: Dextran sodium sulphate (DSS) 2% was added to the drinking water of transgenic mice,
overexpressing the rat α1-AGP gene, to induce acute colitis, thus mimicking the conditions of relapse.
Clinical parameters, inflammatory parameters, and histological analyses on colon sections were per-
formed.
Results: Homozygous α1-AGP-transgenic mice started losing weight and showed rectal bleeding sig-
nificantly earlier than heterozygous transgenic or wild-type mice. Survival time of homozygous
transgenic mice was significantly shorter compared with heterozygous and wild-type mice. The higher
susceptibility of homozygous α1-AGP-transgenic mice to DSS induced acute colitis was also reflected in
higher local myeloperoxidase levels, higher inflammation scores of the colon, and higher systemic lev-
els of interleukin 6 and serum amyloid P component. Local inflammatory parameters were also signifi-
cantly different in heterozygous transgenic mice compared with wild-type mice, indicating a local
dosage effect. In homozygous transgenic mice, significantly higher amounts of bacteria were found in
organs but IgA levels were only slightly lower than those of control mice.
Conclusion: Sufficiently high serum levels of α1-AGP result in a more aggressive development of acute
colitis.
α1-Acid glycoprotein (α1-AGP), an acute phase protein in all
mammals investigated so far,1 is a highly glycosylated protein
of 43 kDa. Due to the presence of sialic acids it is very
negatively charged, its pI being only 2.7.2 α1-AGP is produced
mainly in the liver3 although some extrahepatic synthesis has
also been reported.4–6 In mouse serum, α1-AGP is normally
found at a concentration of 0.2–0.4 mg/ml.7 During an acute
phase condition, the concentration rises 2–5 times, making it
one of the predominant proteins in serum.Although α1-AGP is
an abundant protein, its real physiological significance is not
fully understood. Inhibition of platelet aggregation8 and of
neutrophil function9–11 has been reported. Furthermore,
α1-AGP has been shown to bind lipopolysaccharide.
12 Protec-
tive effects of α1-AGP have been described in vivo.
13–18 Besides
anti-inflammatory properties, α1-AGP has also been shown to
potentiate the secretion by macrophages of proinflammatory
cytokines such as interleukin (IL)-6.19 20
Ulcerative colitis and Crohn’s disease, human inflammatory
bowel diseases (IBDs), are chronic inflammatory disorders of
the intestinal tract, characterised by periods of remission and
relapse. The aetiology of both diseases is unknown. There is
evidence that the pathogenesis involves complex interactions
between genetic, immunological, and environmental
factors,21 including those that affect the nature of the bacterial
flora itself.22 Several experimental models of colitis have been
introduced to study factors that can induce intestinal inflam-
mation. Dextran sodium sulphate (DSS) is an agent that,
when administered to drinking water, induces reproducible
colitis in mice. We show here that transgenic mice expressing
constitutively high levels of α1-AGP in the circulation are
extremely sensitive to IBD induced by administration of DSS
to drinking water.
MATERIALS AND METHODS
Mice
Rat α1-AGP-transgenic mice were generated as described
previously23 by injecting genomic DNA into (C57BL/6×DBA/
2)F1 zygotes; the resulting transgenic mice were back crossed
eight generations into a C57BL/6 background. Heterozygous
transgenic mice from the line 9.5-5 constitutively produce
about 2 mg/ml α1-AGP.
24 This is 10-fold more than wild-type
animals. The colony was propagated by breeding heterozygous
transgenic mice with C57BL/6 female mice; the offspring,
containing heterozygous transgenic and wild-type littermates,
were genotyped at weaning age using an enzyme linked
immunosorbent assay. Blood (100 µl) was collected by
retro-orbital bleeding, after which serum was prepared.
α1-AGP was purified by phenol extraction
25 and coated on the
bottom of an enzyme linked immunosorbent assay plate. After
washing, rat α1-AGP was detected using an antirat α1-AGP
polyclonal antibody (generated by H Baumann in rabbits)
(1/1000) and an antirabbit antibody, conjugated to alkaline
phosphatase (Sigma Chemical Co., St Louis, Missouri, USA;
1/5000). The antirat α1-AGP antibody did not cross react with
mouse α1-AGP. About 50% of the offspring were heterozygous
transgenics. A homozygous transgenic breeding line was also
propagated. Only female mice of 8–12 weeks were used in the
experiments. Both transgenic and control (non-transgenic lit-
termates) mice had comparable body weights. Mice were kept
in a conventional air conditioned mouse room with a 12 hour
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light-dark cycle and received food and water ad libitum. Mice
were bled by retro-ocular bleeding or heart puncture under
ether or tribromoethanol (160 mg/kg) anaesthesia, respec-
tively. Serum was prepared after clotting for 30 minutes at
37°C, removal of the clot, and centrifugation for 15 minutes at
15 000 g.
Disease model
Acute colitis was induced by adding 2% DSS to the drinking
water (tap water) of homozygous and heterozygous α1-AGP-
transgenic and wild-type mice. All mice were weighed daily
and checked for gross bleeding. Four days after the start of
DSS administration, mice were killed using tribromoethanol
(160 mg/kg) and blood was taken by heart puncture. To deter-
mine colon length, histological score, and local levels of
tumour necrosis factor (TNF) and myeloperoxidase (MPO),
the colon was removed and washed with phosphate buffered
saline (PBS). The colon was cut longitudinally and its length
was measured. The distal third of the colon was cut and fixed
in 10% formalin in PBS. Two pieces of colon tissue were cut
from the distal part of the colon, weighed, and stored in ster-
ile PBS or buffer A (0.5% hexadecyltrimethylammonium bro-
mide in 50 mM potassium phosphate buffer, pH 6.0) at −20°C
to determine local TNF and MPO levels, respectively. Sections
of the paraffin embedded material were made longitudinally.
Three 5 µm sections were cut at a distance of 20 µm. The sec-
tions were stained with haematoxylin-eosin. Histological
analysis was performed as described previously26 in a double
blind fashion.Mice were scored individually, each score repre-
senting the mean of three sections. Epithelium was scored as
0 (normal morphology), 1 (loss of goblet cells), 2 (loss of gob-
let cells in large areas), 3 (loss of crypts), and 4 (loss of crypts
in large areas). Infiltration was scored as 0 (no infiltrate), 1
(infiltrate around crypt bases), 2 (infiltrate reaching to the
lamina muscularis mucosa), 3 (extensive infiltration reaching
to the lamina muscularis mucosa, thickening of the mucosa
with abundant oedema), and 4 (infiltration of the lamina
submucosa). The colitis score of individual mice represents the
sum of different histological subscores and had a maximum
value of 8.Mice that were not killed four days after the start of
DSS administration were scored for survival, weighed daily,
and checked for gross bleeding. Six days after DSS administra-
tion, blood was taken under light ether anaesthesia by
retro-ocular bleeding.
Reagents
Bovine serum albumin, bovine α1-AGP, alkaline phosphatase
conjugated antirabbit IgG, p-nitrophenyl phosphate, hexade-
cyltrimethylammoniumbromide, and o-dianisidine dihydro-
chloride were obtained from Sigma Chemical Co. DSS
(molecular weight 40 000) was purchased from ICN Pharma-
ceuticals (Costa Mesa, California, USA). Sheep antimouse
serum amyloid P component (SAP), rabbit antimouse SAP,
mouse SAP standard, and pure human MPO were obtained
from Calbiochem-Novabiochem International (San Diego,
California, USA). Goat antimouse Ig, alkaline phosphatase
conjugated goat antimouse IgA, and a mouse IgA standard
were supplied by Southern Biotechnology Associates (Bir-
mingham, Alabama, USA).
MPO determination
MPO activity was measured as previously described.27 Briefly,
tissue samples were weighed and homogenised by sonication
in buffer A (0.5% hexadecyltrimethylammonium bromide in
50 mM potassium phosphate buffer, pH 6.0). Homogenates
were subjected to three freeze/thaw cycles of five minutes
each. After centrifugation for 20 minutes, 20 µl of the
supernatant of each sample were mixed with 280 µl of buffer
B (0.167 mg/ml o-dianisidine dihydrochloride plus 0.0005%
H2O2 in 50 mM potassium phosphate buffer, pH 6). After 20
minutes, absorbance was measured spectrophotometrically at
490 nm. Pure human MPO was used as a standard. To express
MPO levels per mg of protein, protein determination was per-
formed on the same sample according to a method described
previously.28
IgA determination
To isolate faecal IgA, three fresh faecal pellets were weighed
and dissolved overnight at 4°C in 1 ml of faeces dissolving
solution (0.05% NaN3 and 10% fetal calf serum in PBS). Faeces
were mixed by shaking; after high speed centrifugation,
supernatant was collected and stored at −20°C until use. IgA
ELISA was performed using microtitre plates coated overnight
with a 1/1000 dilution of goat antimouse Ig. After washing,
free places were blocked using 1% bovine serum albumin
solution in PBS (one hour at 37°C). Samples and a standard
were titrated in 1/3 steps in the assay and incubated at 37°C for
one hour. After washing, a second antibody (alkaline
phosphatase conjugated goat antimouse IgA) was added in
1/1000 dilution; plates were incubated for one hour at 37°C.
The assay was developed using p-nitrophenylphosphate;
absorbance was measured at 405 nm.
Measurement of serum parameters
TNF was measured in a cytotoxic assay on WEHI 164 clone 13
cells.29 Briefly, serial dilutions of samples and TNF standards
were incubated with cells in 96 well microtitre plates (30 000
cells/well) in the presence of 1 µg/ml of actinomycin D. After
18 hours of incubation, the number of surviving cells was
determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (detection range of 0.1 pg/ml).
IL-6 was determined as described previously.30 IL-6 depend-
ent 7TD1 cells were cultured in 96 well microtitre plates (7000
cells/well) in the presence of medium, serial dilutions of
serum, or a murine IL-6 standard. After three days of culture,
the number of living cells was determined in a hexosamini-
dase colorimetric assay; titres were assigned by comparing
dilutions of samples and standard needed to obtain half
maximal growth of 7TD1 cells.
SAP was measured by a sandwich ELISA as previously
described.31 Briefly, microtitre plates were coated overnight
with a 1/1000 dilution of sheep antimouse SAP. After washing,
free places were blocked using 1% bovine serum albumin
solution in PBS (one hour at 37°C). Serum and a standard
were diluted 25-fold and titrated in 1/5 steps in triplicate, after
which they were incubated at 37°C for one hour. After wash-
ing, a second antibody (rabbit antimouse SAP) was added in a
1/5000 dilution; plates were incubated for one hour at 37°C,
after which an antirabbit antibody (alkaline phosphatase con-
jugated) was added and incubated for another hour at 37°C.
The assay was developed using p-nitrophenylphosphate;
absorbance was measured at 405 nm.
Rat and mouse AGP were quantitated by rocket immuno-
electrophoresis using specific non-cross reactive polyclonal
antibodies and appropriate standards previously described.23
Bacterial count
Mice were killed by cervical dislocation and perfused with 10
ml of sterile PBS to flush the blood out of the organs. Organs
were removed aseptically and weighed. For homogenisation,
the liver was diluted (w/v) twofold; spleen, kidney, colon, and
lung were diluted (w/v) 10-fold. Suspensions were diluted and
plated on sterile Luria broth. After overnight incubation at
37°C, colony forming units were determined and expressed as
CFU/mg tissue.
Statistics
Mean (SD) values were compared using an unpaired Student’s
t test, with Welch’s correction in case of non-homogeneous
variances. Survival curves (Kaplan-Meier plots) were com-
pared using a log rank test, and final outcomes using Fisher’s
exact test. p<0.05 was considered statistically significant.
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RESULTS
Clinical symptoms during DSS induced colitis
After administration of 2% DSS to the drinking water of
homozygous and heterozygous α1-AGP-transgenic mice and
to wild-type littermates, mice were weighed daily and stools
were checked for the presence of blood. This was done until
most homozygous transgenic mice started to die (day 7). On
day 4, half of the mice from each group (n=18, n=19, and
n=15 for homozygous and heterozygous transgenic and wild-
type mice, respectively) were killed to determine inflamma-
tory parameters. The rest of the mice were followed up for
weight loss and survival. Starting from day 2 of DSS adminis-
tration, a significant difference in weight was found (fig 1A).
The weight of homozygous α1-AGP-transgenic mice was
significantly lower than that of heterozygous transgenic
(p=0.0241) and wild-type (p=0.0035) mice. The difference in
weight loss was most pronounced starting from day 3
(p<0.0001 for difference in weight between homozygous and
heterozygous transgenic mice, and homozygous and wild-type
mice on days 3, 4, 5, and 6). Homozygous transgenic mice
started to show gross bleeding on day 2. On day 3, the number
of homozygous transgenic mice that showed gross bleeding
was significantly higher than in wild-type mice (p=0.0032);
on day 5, all homozygous transgenics showed gross bleeding
(p=0.0003 compared with wild-type mice). In heterozygous
and wild-type mice, gross bleeding was observed on days 3
and 4, respectively; all mice showed gross bleeding on days 7
and 8, respectively. The number of heterozygous transgenic
mice that showed gross bleeding was significantly different
compared with that of wild-type mice on days 6 and 7
(p=0.0202 and p=0.0228, respectively) (table 1). Survival of
homozygous transgenic mice was significantly reduced
compared with heterozygous and wild-type mice (p<0.0001).
Homozygous transgenic mice all died between days 4 and 8
while heterozygous and wild-type mice died between days 7
and 13, and days 8 and 12, respectively (fig 1B).
Exogenous AGP administration in wild-type mice also
resulted in significant enhanced weight loss and earlier
lethality compared with control mice: six days after DSS
administration, wild-type mice which received two intraperi-
toneal injections (on days 0 and 3) of 10 mg of bovine α1-AGP
had a mean weight of 14.6 (0.2) g, mice which received two
injections of 5 mg α1-AGP had a mean weight of 15.9 (0.5) g,
and wild-type mice receiving no α1-AGP had a mean weight of
17.8 (0.1) g (n=6 for each group; p<0.001 for each group
compared with one another). All mice had the same weight at
the onset of the experiment. Eight days after DSS administra-
tion, lethality was 6/6, 1/6 (p=0.0034), and 0/6 (p=0.0005),
respectively.
Local inflammatory parameters
MPO concentration was determined, as a measure of neutro-
phil influx, on a distal piece of the colon of control mice from
each group before DSS administration and four days after DSS
administration. In the latter case, there was a significant
increase in MPO levels in all three groups of mice compared
with control levels (p<0.001). Moreover, there was also a sig-
nificant difference after DSS administration between homo-
zygous and heterozygous transgenic mice, between homo-
zygous transgenic and wild-type mice, and between
heterozygous transgenic and wild-type mice (p<0.001) (fig
2). TNF levels were determined on colon samples of control
mice of each group before and after four days of DSS admin-
istration. Local TNF was not detectable (results not shown).
Finally, inflammation of the distal colon was scored histologi-
cally in a double blind fashion four days after DSS
administration. A significant increase in inflammation score
Figure 1 (A) Per cent weight during dextran sodium sulphate (DSS)
induced acute colitis. DSS 2% was given to the drinking water of
homozygous α1-AGP-transgenic (n=36 and n=17 from day 5),
heterozygous α1-AGP-transgenic (n=38 and n=19 from day 5), and
wild-type mice (n=30 and n=15 from day 5). Weight was recorded
daily. Statistical significance was assessed compared with wild-type
mice. (B) Survival during DSS induced acute colitis. DSS 2% was
given to the drinking water of homozygous α1-AGP-transgenic
(n=18), heterozygous α1-AGP-transgenic (n=19), and wild-type mice
(n=15). Survival was recorded daily. Statistical significance was
assessed compared with wild-type mice. **p<0.01, ***p<0.001.
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Table 1 Appearance of gross bleeding in mice (%) during dextran sodium sulphate
treatment.
Homozygous transgenic Heterozygous transgenic Wild-type
Day 0 0 (n=36); NS 0 (n=38); NS 0 (n=30)
Day 1 0 (n=36); NS 0 (n=38); NS 0 (n=30)
Day 2 6 (n=36); NS 0 (n=38); NS 0 (n=30)
Day 3 25 (n=36);** 3 (n=38); NS 0 (n=30)
Day 4 80 (n=35);*** 19 (n=38); NS 6 (n=30)
Day 5 100 (n=17);*** 61 (n=19); NS 38 (n=15)
Day 6 100 (n=17);*** 78 (n=19);* 50 (n=15)
Day 7 100 (n=5); NS 100 (n=19);* 75 (n=15)
Day 8 ND (n=0) 100 (n=13); NS 100 (n=10)
Significance was calculated using a χ2 test. All values were compared with wild-type mice: *p<0.05,
**p<0.01, ***p<0.001.
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for all three groups of mice was found compared with control
mice before DSS administration (p<0.0001, p=0.0003, and
p=0.044 for homozygous transgenic, heterozygous trans-
genic, and wild-type mice, respectively). There was also a sig-
nificant difference between the various groups four days after
DSS administration. Homozygous transgenic mice had a
significantly higher inflammatory score than heterozygous
transgenic (p<0.0001) and wild-type mice (p<0.0001).
Moreover, heterozygous transgenic mice also had a signifi-
cantly higher inflammation score compared with wild-type
mice (p=0.0056) (fig 3A). A representative example of colon
sections of negative controls, and wild-type, homozygous, and
heterozygous transgenic mice four days after 2% DSS admin-
istration is shown in fig 3B. Negative controls showed no signs
of crypt damage or inflammatory infiltrate. Wild-type mice
showed only mild inflammation consisting of local, and in
some cases more general, loss of goblet cells and inflammatory
infiltrate localised to the crypt base. In heterozygous
transgenic mice, crypt damage was in most cases confined to
general loss of goblet cells or local crypt loss while inflamma-
tory infiltrate extended from the crypt base to the lamina
muscularis mucosa, with or without signs of oedema. In
homozygous transgenic mice, crypt damage ranged from local
to general crypt destruction; inflammatory infiltrate reached
the lamina muscularis mucosa, with abundant oedema, or
even the submucosa. In all cases, inflammatory infiltrate con-
sisted of a mixture of granulocytes and lymphocytes.
Systemic inflammatory parameters
Four days after DSS administration, half of the mice in each
group were killed and blood was taken by heart puncture. The
surviving mice were bled by retro-ocular bleeding six days
after DSS administration. Cytokine, SAP, and mouse or rat
AGP levels were determined in serum samples as a systemic
measure of inflammation. IL-6 levels were increased in the
three groups of mice four days after DSS administration com-
pared with control mice (p=0.0004 for homozygous trans-
genic mice and p=0.0159 for wild-type mice); the increase in
IL-6 concentration in the serum of heterozygous transgenic
mice was not statistically significant. There was also a signifi-
cant difference in IL-6 levels four days after DSS administra-
tion between homozygous transgenic and heterozygous
transgenic mice on the one hand and between homozygous
transgenic and wild-type mice on the other (p=0.0026 and
p=0.0002, respectively) (fig 4). TNFwas not detected in serum
samples, neither four days nor six days after DSS administra-
tion (results not shown). SAP levels in serum four days after
DSS administration were significantly increased in homo-
zygous transgenic mice (p=0.0059) but not in heterozygous
transgenic and wild-type mice. Six days after DSS administra-
tion there was a significant increase in SAP levels in
homozygous and heterozygous transgenic mice. The increase
in SAP levels in wild-type mice was not statistically
significant. We also found a significant difference in SAP lev-
els six days after DSS administration compared with four days
after DSS administration in the three groups of mice
(p<0.0001, p=0.0042, and p=0.0037 for homozygous trans-
genic, heterozygous transgenic, and wild-type mice, respec-
tively). Among the groups, there was a significant difference
four and six days after DSS administration between homo-
zygous and heterozygous transgenic mice on the one hand
and between homozygous and wild-type mice on the other
(p<0.0001 for all) (fig 5A). Mouse AGP levels in wild-type
Figure 2 Local myeloperoxidase (MPO) levels after dextran sodium
sulphate (DSS) treatment. MPO levels were determined in colon
samples of homozygous α1-AGP-transgenic (n=18), heterozygous
α1-AGP-transgenic (n=19), and wild-type mice (n=15) four days after
administration of 2% DSS and compared with negative controls of
the corresponding genotype (n=5 for each group). Statistical
significance was assessed compared with homozygous transgenic
mice. ***p<0.001.
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Figure 3 (A) Histological score after dextran sodium sulphate
(DSS) treatment. Four days after 2% DSS treatment, the histological
score was determined from the distal part of the colon from
homozygous α1-AGP-transgenic (n=18), heterozygous
α1-AGP-transgenic (n=19), and wild-type mice (n=15) and compared
with negative controls of the corresponding genotype (n=5 for each
group). Statistical significance values are based on homozygous and
heterozygous transgenic versus wild-type mice, and homozygous
versus heterozygous transgenic mice: **p<0.01, ***p<0.001. (B)
Representative distal colon sections (100×) stained with
haematoxylin-eosin. (a) Section of a negative control (no DSS
treatment) showing normal crypt morphology, with crypt bases
resting on the lamina muscularis mucosa, and no inflammatory
infiltrate. (b) Section of a wild-type mouse four days after DSS
treatment. There is local loss of goblet cells and some inflammatory
infiltrate at the crypt base which is no longer resting on the lamina
muscularis mucosa. (c) Section of a heterozygous transgenic mouse
showing local crypt destruction and inflammatory infiltrate reaching
to the lamina muscularis mucosa. (d) Section of a homozygous
transgenic mouse with total destruction of crypt structure and
inflammatory infiltrate reaching into the submucosa.
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mice (fig 5B) and rat AGP levels in heterozygous and
homozygous transgenic mice (fig 5C) were significantly
increased six days after DSS administration (p<0.001). Rat
AGP levels in homozygous transgenic mice were almost twice
as high as those in heterozygous transgenic mice.
Bacterial counts in organs
To test whether tissue destruction would lead to increased
spread of luminal bacteria to other organs, organs were
flushed, removed aseptically, weighed, and homogenised.
Homogenised tissues were plated out and the number of bac-
teria was counted. In lung, significantly more bacteria were
observed in homozygous transgenic mice compared with
heterozygous transgenic and wild-type mice (p=0.0119 and
p=0.0007, respectively). In the liver and colon, we found sig-
nificantly more bacteria in homozygous mice compared with
wild-type mice (p=0.0291 and p=0.0331, respectively).
Although bacterial counts were also higher in the spleen of
transgenic mice, the difference was not statistically significant
compared with wild-type mice (fig 6).
IgA levels in faeces were investigated to determine whether
an increase in bacterial load in homozygous transgenic mice
was due to decreased production of IgA in the colon. However,
no significant difference in concentrations of IgA in the three
groups of mice was detected (fig 7).
DISCUSSION
Acute colitis, induced by administration of DSS to the drink-
ing water of mice, is a useful model for studying the
pathophysiological aspects of colonic inflammatory diseases
such as IBD, for evaluating new therapeutic targets and
agents,32 33 or to study relapse during IBD.34 Clinical symptoms
following DSS administration include haemocult positive and
loose stools, followed by diarrhoea, gross bleeding, and weight
loss. The earliest histological observation is loss of goblet cells,
followed by crypt loss, which precedes an increase in mucosal
permeability. Inflammation occurs secondary to crypt loss.
The inflammatory infiltrate mainly consists of MPO positive
granulocytes.26 35
The mechanism of DSS induced colitis is not fully
understood. DSS is thought to induce mucosal injury as mice
deficient in key mediators of protection and/or repair mecha-
nisms in the colonic mucosa and of factors preservingmucosal
integrity of the colon have considerably increased susceptibil-
ity to DSS.36–38 Inflammation is the result of subsequent activa-
tion of macrophages, resulting in cytokine mediated
cytotoxicity.39–43 As it was found that high serum concentra-
tions of α1-AGP are positively correlated with the risk of
relapse in IBD,44–46 we investigated a possible role of high
serum concentrations of α1-AGP in the development of acute
colitis. We found that during DSS administration, homo-
zygous α1-AGP-transgenic mice started to show clinical signs
of illness much earlier than heterozygous transgenic or wild-
type controls. Weight loss and gross bleeding appeared signifi-
cantly earlier in transgenic mice compared with wild-type
mice, and survival of homozygous transgenic mice was
significantly reduced compared with heterozygous transgenic
and wild-type mice. The clinical data clearly show a difference
in response to DSS between homozygous transgenics on the
one hand and heterozygous transgenics andwild-typemice on
the other. However, except for a minor but statistically signifi-
cant difference in appearance of gross bleeding, there was no
significant difference in clinical parameters between hetero-
zygous transgenics and wild-type mice. The fact that
Figure 4 Interleukin 6 (IL-6) serum concentration during dextran
sodium sulphate (DSS) treatment. Four days after DSS treatment, IL-6
levels were determined in the serum of homozygous
α1-AGP-transgenic (n=36), heterozygous α1-AGP-transgenic (n=38),
and wild-type mice (n=30). IL-6 levels were compared with negative
controls of the corresponding genotype (n=5 for each group).
Statistical significance was assessed compared with homozygous
transgenic mice: **p<0.01, ***p<0.001.
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Figure 5 (A) Serum amyloid P component (SAP) serum
concentrations during dextran sodium sulphate (DSS) treatment. Four
and six days after DSS treatment SAP levels were determined in the
serum of homozygous α1-AGP-transgenic (n=36 on day 4 and n=17
on day 6), heterozygous α1-AGP-transgenic (n=38 on day 4 and
n=19 on day 6), and wild-type mice (n=30 on day 4 and n=15 on
day 6). SAP levels were compared with negative controls of the
corresponding genotype (n=5 for each group). Statistical
significance was assessed compared with homozygous transgenic
mice. (B) Mouse α1-AGP serum concentrations in wild-type mice
before and during DSS administration (n=15). (C) Rat α1-AGP levels
in homozygous and heterozygous transgenic mice before (n=5) and
during DSS administration (n=17 and n=19 on day 4 and day 6 for
homozygous and heterozygous α1-AGP transgenic mice,
respectively). *p<0.05, ***p<0.001.
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homozygous transgenic mice show clinical signs of illness
relatively fast indicates that the effect of α1-AGP is probably at
one of the very early stages in the pathogenesis of DSS
induced colitis. Accordingly, administration of exogenous
α1-AGP to wild-type mice also led to increased lethality and
weight loss in α1-AGP treated mice compared with controls
receiving no α1-AGP.
Determination of local inflammatory parameters four days
after DSS administration revealed a dosage effect of α1-AGP.
Histological observation and local MPO levels clearly showed
that α1-AGP-transgenic mice have a much worse
inflammation/pathology than wild-type mice, homozygous
transgenic mice being even more affected than heterozygous
transgenics. Local TNF bioactivity was not detected in any of
the colon samples, even using a very sensitive bioassay (detec-
tion limit of 0.1 pg/ml). Although upregulation of TNF is dem-
onstrated by several investigators,40 47 others did not detect
TNF bioactivity in colon or serum samples.48
Systemic inflammatory parameters, including serum IL-6
and SAP levels, again showed no significant differences
between heterozygous and wild-type mice but were signifi-
cantly higher in homozygous transgenics compared with
heterozygous transgenic and wild-type mice. Again, we could
not detect any TNF bioactivity in serum samples both in con-
trast with and in agreement with others.40 47 48 Mouse or rat
AGP levels were also increased after DSS administration.
Although α1-AGP levels only started to increase six days after
DSS administration, the initial high concentration is probably
sufficient to synergise in the development of acute colitis.
Therefore, it seems that local inflammatory parameters are
more influenced by the presence of α1-AGP while this is not
the case for systemic inflammatory parameters.
The number of bacteria in the lung, liver, and colon was sig-
nificantly higher in homozygous compared with wild-type
mice four days after DSS administration. In spleen there was
an increase in bacterial load in transgenic mice although this
was not significant. This observation is in agreement with
previously reported results49 showing an increase in Gram
negative bacteria in the liver and spleen of terminally ill ani-
mals. It has already been suggested that some bacterial organ-
isms may invade the mucosa after induction of toxic injury by
DSS on colonic epithelial cells.37 Moreover, in acute DSS colitis,
treatment with antibiotics led to improvement in histological
parameters and colon length.36 50 This suggests that an
increase in bacterial load and loss of tolerance, leading to
spread of bacteria in tissues, may contribute to the disease
process.
IgA is produced to defend mucosal surfaces from environ-
mental organisms.51 As α1-AGP is known to have an inhibitory
effect on activation of lymphocytes, by measuring IgA levels
we investigated whether an increase in bacterial load in trans-
genic mice can be ascribed to decreased tolerance against
intestinal bacteria. However, there was no difference in IgA
levels between the three groups of mice.
Macrophages play an important role in the acute DSS
model as they can phagocytose DSS, leading to activation of
macrophages,39 40 which can contribute to tissue damage. As
α1-AGP can stimulate macrophages to release proinflamma-
tory cytokines such as IL-1,19 this could result in a positive
feedback loop; the high local concentration of α1-AGP could
have an exponential effect on cytokine release and could
stimulate leucocyte recruitment and activation whereby more
macrophages and other inflammatory cells such as neu-
trophils are activated and contribute to tissue damage. Indeed,
we have shown that there was more MPO in transgenic mice
(a dose dependent effect).
In conclusion, we have shown that α1-AGP-transgenic mice
have an increased susceptibility to DSS induced colitis
compared with wild-type mice. Clinically and systemically
there is little difference in the parameters observed between
heterozygous transgenic and wild-type mice. However, when
considering local parameters, such as MPO levels and inflam-
mation score, there was a dosage effect of α1-AGP. Homo-
zygous transgenic mice are more susceptible than hetero-
zygous transgenic mice; the latter are clearly more susceptible
to DSS induced colitis than wild-type mice. Our results
suggest that high levels of α1-AGP can have a synergistic effect
with stimuli that can provoke colitis.
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